Entering China’s Intraocular Lens Market: Evolving NMPA Requirements for Foreign Manufacturers

China continues to position itself as one of the most attractive yet complex markets for medical device manufacturers, particularly in high-risk and innovation-driven segments such as ophthalmology.

Recent insights into intraocular lens (IOL) registration highlight how the regulatory landscape is evolving under the National Medical Products Administration, with increasing emphasis on clinical evidence, product quality, and lifecycle compliance.

As demand for advanced vision correction solutions grows, understanding these regulatory expectations is becoming essential for manufacturers seeking successful market entry into China.

A Highly Regulated but High-Opportunity Market

China represents a significant opportunity for ophthalmic medical device companies, with strong demand for intraocular lenses driven by an ageing population and increasing access to healthcare.

However, regulatory approval remains highly selective.

Recent data shows that while ophthalmology devices are among the most imported categories, approval rates for intraocular lenses remain limited, with only a small number of approvals granted in recent years, highlighting the stringent and competitive nature of the regulatory process.

This underscores a key reality: market demand alone does not guarantee approval; a regulatory strategy is critical.

Strengthening Regulatory Expectations for IOLs

Intraocular lenses are classified as high-risk (Class III) medical devices in China, meaning they are subject to the most rigorous level of regulatory scrutiny.

The National Medical Products Administration places particular focus on:

• Material safety and composition transparency

• Non-clinical performance and stability testing

• Biocompatibility and preclinical safety data

• Robust clinical evaluation and evidence generation

Given that IOLs are permanently implanted and directly impact visual outcomes, regulators require comprehensive and well-structured evidence to support product approval.

Increasing Importance of Clinical and Technical Guidelines

China has introduced more structured guidance to standardise expectations for intraocular lens registration.

Key developments include:

• Defined requirements for clinical trial design and endpoints

• Clear expectations for patient selection and follow-up periods

• Detailed guidance on registration dossier structure and technical documentation

  
  

These updates reduce ambiguity but also raise the bar, requiring manufacturers to align their clinical and regulatory strategies from the early stages of product development.

A Shift Toward Lifecycle Compliance

Beyond product approval, China’s regulatory system is evolving toward full lifecycle oversight.

Recent regulatory reforms signal:

• Stricter documentation and compliance requirements

• Increased legal accountability for manufacturers

• Expanded Good Manufacturing Practice (GMP) expectations

• Stronger post-market surveillance and enforcement mechanisms

This reflects a broader transition from a submission-focused system to a continuous compliance model, where manufacturers must maintain regulatory alignment throughout the product lifecycle.

Key Entry Requirement: Local Legal Representation

One of the most critical requirements for foreign manufacturers is the appointment of a local legal agent in China.

This entity is responsible for:

• Managing communication with the National Medical Products Administration

• Submitting registration applications

• Overseeing post-market obligations

The choice of legal agent can significantly impact regulatory control, flexibility, and long-term market strategy, making it a key strategic decision for companies entering China.

Strategic Implications for Manufacturers

The evolving regulatory environment in China highlights several important considerations:

1. Early Regulatory Alignment is Essential

Global approval strategies cannot be directly applied to China. Companies must adapt to local regulatory expectations from the outset.

2. Clinical Evidence is a Critical Success Factor

Robust and locally relevant clinical data play a central role in securing approval.

3. Compliance is Ongoing, Not One-Time

Manufacturers must prepare for continuous regulatory obligations beyond initial approval.

China’s Direction: Precision, Control, and Innovation

China’s regulatory framework is becoming increasingly structured, predictable, and enforceable.

At the same time, the National Medical Products Administration is shifting toward supporting innovation while maintaining strict oversight, particularly for high-risk and implantable devices.

For intraocular lens manufacturers, success in China will depend on the ability to combine innovation with a well-executed regulatory strategy.

How ARQon Can Support

Navigating China’s medical device regulatory landscape requires specialised expertise and continuous monitoring of evolving requirements.

At ARQon International Group, we support manufacturers with:

• China's medical device registration strategy

• Regulatory intelligence and compliance planning

• Clinical and technical documentation support

• Market entry and lifecycle management

With the increasing complexity of China’s regulatory system, having the right partner is essential to achieving efficient, compliant, and successful market access.